AU2018288832B2 - Assessing transplant complication risk with total cell-free DNA - Google Patents

Assessing transplant complication risk with total cell-free DNA Download PDF

Info

Publication number
AU2018288832B2
AU2018288832B2 AU2018288832A AU2018288832A AU2018288832B2 AU 2018288832 B2 AU2018288832 B2 AU 2018288832B2 AU 2018288832 A AU2018288832 A AU 2018288832A AU 2018288832 A AU2018288832 A AU 2018288832A AU 2018288832 B2 AU2018288832 B2 AU 2018288832B2
Authority
AU
Australia
Prior art keywords
total
dna
subject
amount
cfdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018288832A
Other languages
English (en)
Other versions
AU2018288832A1 (en
Inventor
Aoy Tomita Mitchell
Michael Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of AU2018288832A1 publication Critical patent/AU2018288832A1/en
Application granted granted Critical
Publication of AU2018288832B2 publication Critical patent/AU2018288832B2/en
Priority to AU2025204208A priority Critical patent/AU2025204208A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/101—Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018288832A 2017-06-20 2018-06-20 Assessing transplant complication risk with total cell-free DNA Active AU2018288832B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204208A AU2025204208A1 (en) 2017-06-20 2025-06-05 Assessing transplant complication risk with total cell-free DNA

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762522533P 2017-06-20 2017-06-20
US62/522,533 2017-06-20
US201762572556P 2017-10-15 2017-10-15
US62/572,556 2017-10-15
PCT/US2018/038598 WO2018237075A1 (en) 2017-06-20 2018-06-20 Assessing transplant complication risk with total cell-free dna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204208A Division AU2025204208A1 (en) 2017-06-20 2025-06-05 Assessing transplant complication risk with total cell-free DNA

Publications (2)

Publication Number Publication Date
AU2018288832A1 AU2018288832A1 (en) 2020-01-16
AU2018288832B2 true AU2018288832B2 (en) 2025-03-06

Family

ID=64735781

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018288832A Active AU2018288832B2 (en) 2017-06-20 2018-06-20 Assessing transplant complication risk with total cell-free DNA
AU2025204208A Pending AU2025204208A1 (en) 2017-06-20 2025-06-05 Assessing transplant complication risk with total cell-free DNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204208A Pending AU2025204208A1 (en) 2017-06-20 2025-06-05 Assessing transplant complication risk with total cell-free DNA

Country Status (8)

Country Link
US (2) US11773434B2 (https=)
EP (2) EP4488387A3 (https=)
JP (1) JP2020524519A (https=)
CN (1) CN110945136A (https=)
AU (2) AU2018288832B2 (https=)
CA (1) CA3067637A1 (https=)
IL (1) IL271460A (https=)
WO (1) WO2018237075A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2572003A4 (en) 2010-05-18 2016-01-13 Natera Inc METHOD FOR NONINVASIVE PRANATAL PLOIDIE ASSIGNMENT
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
WO2012088456A2 (en) 2010-12-22 2012-06-28 Natera, Inc. Methods for non-invasive prenatal paternity testing
AU2011358564B9 (en) 2011-02-09 2017-07-13 Natera, Inc Methods for non-invasive prenatal ploidy calling
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP3957749A1 (en) 2014-04-21 2022-02-23 Natera, Inc. Detecting tumour specific mutations in biopsies with whole exome sequencing and in cell-free samples
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
JP2021506342A (ja) 2017-12-14 2021-02-22 ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 移植のための移植片適合性の評価
CA3090426A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020206290A1 (en) * 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
EP3980559A1 (en) 2019-06-06 2022-04-13 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
CN111667883B (zh) * 2020-06-03 2021-01-22 四川大学 一种基于复合微单倍型焦磷酸测序图谱解析的法医学混合dna的分析方法
US20230399697A1 (en) * 2020-11-09 2023-12-14 The Medical College Of Wisconsin, Inc. Assessing risk with pre-operative total cell-free dna
WO2025079958A1 (ko) * 2023-10-11 2025-04-17 고려대학교 산학협력단 높은 처리량의 돌연변이 특이적 아답터 리게이션 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013159035A2 (en) * 2012-04-19 2013-10-24 Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5569582A (en) 1991-07-15 1996-10-29 Institute Of Molecular Biology & Technology Rapid amplification and detection of nucleic acids
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
AU750767B2 (en) 1998-01-23 2002-07-25 Immunex Corporation ACPL DNA and polypeptides
US20030148301A1 (en) 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
EP1325963B1 (en) 2001-12-24 2006-09-27 Wolfgang Prof. Holzgreve Method for non-invasive diagnosis of transplantations and transfusions
US6977162B2 (en) 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
JP4116856B2 (ja) 2002-10-02 2008-07-09 富士フイルム株式会社 １塩基多型の検出方法
WO2004078999A1 (en) 2003-03-05 2004-09-16 Genetic Technologies Limited Identification of fetal dna and fetal cell markers in maternal plasma or serum
US20060014179A1 (en) 2004-06-02 2006-01-19 New England Biolabs, Inc. Inferring function from shotgun sequencing data
WO2006047483A2 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
EP2351858B1 (en) 2006-02-28 2014-12-31 University of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
US8609338B2 (en) 2006-02-28 2013-12-17 University Of Louisville Research Foundation, Inc. Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
LT2557517T (lt) 2007-07-23 2023-01-10 The Chinese University Of Hong Kong Nukleino rūgščių sekos disbalanso nustatymas
US20100326218A1 (en) 2007-09-27 2010-12-30 Michael Boeckh Identifying a subject with an increased risk of invasive mold infection
US8748113B2 (en) 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
CN104195227B (zh) 2008-11-07 2017-04-12 适应生物技术公司 通过序列分析监测状况的方法
WO2010087985A2 (en) 2009-01-28 2010-08-05 Yale University Novel markers for detection of complications resulting from in utero encounters
US20120190663A1 (en) 2009-08-06 2012-07-26 Cedars-Sinai Medical Center Use of free dna as an early predictor of severity in acute pancreatitis
HUE052213T2 (hu) 2009-11-06 2021-04-28 Univ Leland Stanford Junior Grafitkilökõdés nem invazív diagnosztizálása szervátültetett betegekben
US20120010085A1 (en) 2010-01-19 2012-01-12 Rava Richard P Methods for determining fraction of fetal nucleic acids in maternal samples
US20130143219A1 (en) 2010-01-28 2013-06-06 Medical College of Wisconsin Inc. Methods and compositions for high yield, specific amplification
CN102892901B (zh) 2010-03-24 2015-11-25 凸版印刷株式会社 利用竞争性引物的目标碱基序列的检测方法
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
AU2011358564B9 (en) 2011-02-09 2017-07-13 Natera, Inc Methods for non-invasive prenatal ploidy calling
WO2012113780A1 (en) 2011-02-21 2012-08-30 Qiagen Gmbh Method for quantifying human dna
WO2012122374A2 (en) 2011-03-08 2012-09-13 Children's Medical Center Corporation Non-invasive methods for diagnosing chronic organ transplant rejection
BR112014014664B1 (pt) 2011-12-16 2023-02-28 Basf Agrochemical Products, B.V Método para analisar um gene ahasl de planta e kit para analisar um gene ahasl de planta
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
JP6285436B2 (ja) 2012-08-03 2018-02-28 フェリング ベスローテン フェンノートシャップ 雌性不妊症のための治療標的および診断マーカーとしての無細胞ｄｎａ
US10988803B2 (en) 2014-12-29 2021-04-27 Life Genetics Lab, Llc Multiplexed assay for quantitating and assessing integrity of cell-free DNA in biological fluids for cancer diagnosis, prognosis and surveillance
WO2014143989A1 (en) 2013-03-15 2014-09-18 Medical College Of Wisconsin, Inc. Fetal well being surveillance using fetal specific cell free dna
GB201304810D0 (en) 2013-03-15 2013-05-01 Isis Innovation Assay
DK3004388T4 (da) 2013-05-29 2023-08-28 Chronix Biomedical Påvisning og kvantificering af cellefrit dna fra donor i kredsløbet hos organtransplantatmodtagere
WO2015026873A1 (en) 2013-08-19 2015-02-26 Singular Bio, Inc. Assays for single molecule detection and use thereof
EP3041955A4 (en) 2013-09-06 2017-05-03 Immucor GTI Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
WO2015069933A1 (en) 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
WO2015178978A2 (en) 2014-02-14 2015-11-26 The Board Of Regents Of The University Of Texas System Strand exchange hairpin primers that give high allelic discrimination
CA2970916C (en) 2014-03-14 2025-02-04 Caredx, Inc. METHODS FOR MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT
EP3957749A1 (en) 2014-04-21 2022-02-23 Natera, Inc. Detecting tumour specific mutations in biopsies with whole exome sequencing and in cell-free samples
WO2015169947A1 (en) 2014-05-09 2015-11-12 Lifecodexx Ag Detection of dna that originates from a specific cell-type and related methods
EP3164503B1 (en) 2014-07-03 2024-08-28 Agilent Technologies, Inc. Methods for non-invasive detection of transplant health or rejection
CN115029342B (zh) 2014-08-22 2025-04-08 分析生物科学有限公司 用于无细胞dna的定量遗传分析的方法
WO2016063122A1 (en) 2014-10-20 2016-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a subject for a cancer
WO2016123698A1 (en) 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US20180142296A1 (en) 2015-04-30 2018-05-24 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna
CN108291330A (zh) 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
JP6884774B2 (ja) 2015-10-22 2021-06-09 サイトソーベンツ・コーポレーション 生体液よりタンパク質ベースの毒素とカリウムを除去するための多機能性の血液適合性多孔性ポリマービーズ吸着剤
EP3384050A4 (en) 2015-12-03 2019-07-31 Alfred Health MONITORING THE TREATMENT OR PROGRESSION OF MYELOMA
JP2019518437A (ja) 2016-04-29 2019-07-04 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 多重／最適化ミスマッチ増幅（ｍｏｍａ）−がんの評価のためのリアルタイムｐｃｒ
EP3449018A4 (en) 2016-04-29 2019-11-06 The Medical College of Wisconsin, Inc. REAL-TIME PCR WITH MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA) FOR THE EVALUATION OF FETAL WELL-BEING
BR112018072196A2 (pt) * 2016-04-29 2019-02-12 Medical College Wisconsin Inc amplificação de incompatibilidade otimizada multiplexadas (moma) - número do alvo
CN110114477A (zh) * 2016-11-02 2019-08-09 威斯康星州立大学医学院 用于使用总的和特异性无细胞dna评估风险的方法
CA3042722A1 (en) 2016-11-02 2018-05-11 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
CA3067635A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
AU2018288835A1 (en) 2017-06-20 2020-01-16 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free DNA
WO2019006561A1 (en) 2017-07-07 2019-01-10 Mcmaster University RISK ASSESSMENT TOOL FOR PATIENTS WITH SEPSIS
WO2019008408A1 (en) 2017-07-07 2019-01-10 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR DETERMINING WHETHER A PATIENT SUFFERING FROM MYELOPROLIFERATIVE NEOPLASM IS AT RISK OF THROMBOSIS
ES2913665T3 (es) 2017-09-18 2022-06-03 Santersus Ag Método y dispositivo para la purificación de sangre a partir de ADN celular libre en circulación
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
JP2021506342A (ja) 2017-12-14 2021-02-22 ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 移植のための移植片適合性の評価
WO2019217918A1 (en) 2018-05-10 2019-11-14 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
US20200109449A1 (en) 2018-10-09 2020-04-09 Tai Diagnostics, Inc. Cell lysis assay for cell-free dna analysis
EP3899033A4 (en) 2018-12-17 2022-10-19 The Medical College of Wisconsin, Inc. Assessing risk with total cell-free dna
WO2020206292A2 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free dna
WO2020206269A1 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
WO2020206290A1 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013159035A2 (en) * 2012-04-19 2013-10-24 Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARCIA MOREIRA ET AL: "Cell-Free DNA as a Noninvasive Acute Rejection Marker in Renal Transplantation", CLINICAL CHEMISTRY, vol. 55, 2009, pages 1958 - 1966 *

Also Published As

Publication number Publication date
EP3642353C0 (en) 2025-03-05
CN110945136A (zh) 2020-03-31
EP3642353B1 (en) 2025-03-05
EP3642353A1 (en) 2020-04-29
WO2018237075A1 (en) 2018-12-27
EP3642353A4 (en) 2021-02-24
EP4488387A2 (en) 2025-01-08
JP2020524519A (ja) 2020-08-20
EP4488387A3 (en) 2025-07-23
US11773434B2 (en) 2023-10-03
AU2018288832A1 (en) 2020-01-16
IL271460A (en) 2020-01-30
US20240026437A1 (en) 2024-01-25
AU2025204208A1 (en) 2025-06-26
US20210139969A1 (en) 2021-05-13
CA3067637A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
US20240026437A1 (en) Assessing transplant complication risk with total cell-free dna
US20230167499A1 (en) Methods for assessing risk using total cell-free dna
US20220267849A1 (en) Transplant patient monitoring with cell-free dna
JP7323462B2 (ja) セルフリーｄｎａによる移植患者のモニタリング
US20220356522A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
EP3449019B1 (en) Multiplexed optimized mismatch amplification (moma)-target number
US20220145391A1 (en) Assessing risk with total cell-free dna
US20210139988A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
US20190360033A1 (en) Methods for assessing risk using mismatch amplification and statistical methods
US20190367972A1 (en) Methods for assessing risk using total and specific cell-free dna
WO2021236964A1 (en) Methods for measuring total cell-free dna using alu fragments
HK40029115B (en) Assessing transplant complication risk with total cell-free dna
HK40029115A (en) Assessing transplant complication risk with total cell-free dna
HK40005635B (en) Multiplexed optimized mismatch amplification (moma)-target number
HK40005635A (en) Multiplexed optimized mismatch amplification (moma)-target number

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)